H-CYTE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
For the nine months, sales was USD 1.29 million compared to USD 1.69 million a year ago. Net loss was USD 4.05 million compared to USD 4.9 million a year ago. Basic loss per share from continuing operations was USD 30 compared to USD 50 a year ago. Diluted loss per share from continuing operations was USD 30 compared to USD 50 a year ago.